Insider Selling: Audentes Therapeutics, Inc. (BOLD) SVP Sells 10,000 Shares of Stock
Audentes Therapeutics, Inc. (NASDAQ:BOLD) SVP Mary Newman sold 10,000 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $26.84, for a total transaction of $268,400.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Mary Newman also recently made the following trade(s):
- On Thursday, August 24th, Mary Newman sold 10,000 shares of Audentes Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00.
Audentes Therapeutics, Inc. (NASDAQ:BOLD) traded up $0.18 on Friday, reaching $27.57. 183,915 shares of the company’s stock were exchanged, compared to its average volume of 142,870. Audentes Therapeutics, Inc. has a one year low of $13.90 and a one year high of $33.43.
WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/11/17/insider-selling-audentes-therapeutics-inc-bold-svp-sells-10000-shares-of-stock.html.
BOLD has been the subject of a number of recent analyst reports. ValuEngine cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, October 13th. Raymond James Financial, Inc. initiated coverage on shares of Audentes Therapeutics in a report on Thursday, October 12th. They issued a “market perform” rating for the company. Bank of America Corporation reaffirmed a “buy” rating and issued a $33.00 price objective (up previously from $23.00) on shares of Audentes Therapeutics in a report on Friday, September 22nd. Zacks Investment Research cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $29.00 price objective (up previously from $22.00) on shares of Audentes Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Audentes Therapeutics currently has a consensus rating of “Hold” and an average price target of $27.17.
Hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its stake in shares of Audentes Therapeutics by 278.5% during the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 5,700 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Audentes Therapeutics during the third quarter worth about $143,000. Nationwide Fund Advisors increased its stake in shares of Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 6,384 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Audentes Therapeutics during the second quarter worth about $210,000. Finally, Rhumbline Advisers purchased a new stake in shares of Audentes Therapeutics during the second quarter worth about $252,000. 77.19% of the stock is owned by institutional investors and hedge funds.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.